The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting Agents
Speakers: Luz Fonacier, MD, Professor of MedicineMarcus Maurer, MD, Professor Dermatology and Allergy
Duration: 60 minutes
Presented on: January 9, 2023
Luz Fonacier, MD
Luz Fonacier, MD
Professor of MedicineLuz Fonacier, MD, is a Professor of Medicine at New York University (NYU)-Long Island School of Medicine. She is Head of Allergy and the Training Program Director in NYU Langone Hospital-Long Island. Because of her training in dermatology, allergy, and immunology, her special interests are the dermatologic manifestations of allergic diseases. Prior to her current positions, Dr. Fonacier was President and Chair of the American College of Allergy, Asthma and Immunology (ACAAI); she was the first to hold both positions simultaneously. Dr. Fonacier is the recipient of many awards including the ACAAI “Women in Allergy Award” and the 1998 Presidential Award of the Asian Pacific Association of Allergy and Clinical Immunology. Also, she is the first honorary Fellow of the Philippine Society of AAI.
Marcus Maurer, MD
Marcus Maurer, MD
Professor Dermatology and AllergyMarcus Maurer, MD, is the Professor Dermatology and Allergy at Charité – Universitätsmedizin in Berlin, Germany. In addition, he is the Co-Director for the Fraunhofer Site for Allergology and Immunology of the Fraunhofer Translational Medicine and Pharmacology ITMP and Executive Director for the Institute of Allergology. Dr. Maurer is a coordinator of the Global Allergy and Asthma European Networks of urticaria and angioedema centers of reference and excellence. His areas of clinical interest include angioedema, urticaria, mastocytosis, pruritus, skin infections, and allergic diseases. His research is focused on the biology of mast cells, neuroimmunology, inflammation, innate immunity, and tolerance. Furthermore, Dr. Maurer has supervised more than 60 clinical trials, phase 1 through 4.
The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting AgentsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA).
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
LIVE RELEASE DATEMonday, January 9, 2023, from 3:00-4:00pm ET
TARGET AUDIENCEThe educational design of this activity addresses the needs of dermatologists, allergists, specialty nurse practitioners, and specialty physician assistants involved in the treatment of patients with chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU).
STATEMENT OF NEED/PROGRAM OVERVIEWPatients often suffer for years before a diagnosis of chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU) can be confirmed. Inadequately controlled CSU or CIndU interferes with sleep and often leads to depression, anxiety, severely impaired quality of life, and frequent healthcare visits. Clinicians are also challenged to diagnose and determine the subtype of CIndU based on its trigger and trigger threshold.
Join a panel of expert dermatology and allergy clinicians to discuss the tremendous burden of CSU and CIndU for patients and learn how to apply up-to-date evidence and recommendations to quickly confirm a diagnosis. Panelist will also explore the most recent evidence-based guidelines for the management of CSU and CIndU and review strategies to quickly step-up treatment based on routine assessments of disease activity, impact, and control. Clinicians will recognize the need to identify urticaria subtypes, understand the most recent evidence for emerging targeted treatment options for CSU, and the subgroup of CIndU-cold patients who are refractory to H1-antihistamines.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Summarize the relationships between triggers of Chronic Inducible Urticaria (CIndU) and underlying pathophysiologic pathways
- Apply a comprehensive approach to the diagnosis of urticaria, confidently identifying CSU, CIndU and Chronic Inducible Cold Urticaria (CIndU-cold)
- Optimize treatment of CSU and CIndU by stepping up treatment with antihistamine as needed based on routine assessment of disease activity, impact, and control
- Explain the mechanism of action and current efficacy and safety data for emerging treatment options targeting type 2 inflammation in relieving burdensome symptoms of antihistamine refractory CSU and CIndU-cold
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 60 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPSGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Luz Fonacier, MD
Professor of Medicine
NYU Long Island School of Medicine
Head of Allergy and Training Program Director
NYU Langone Health-Long Island
Consulting Fee (e.g., Advisory Board): AbbVie, Leo Pharma, Lilly, Pfizer, Regeneron
Contracted Research: AstraZeneca, Pfizer, Regeneron, Shire
Marcus Maurer, MD
Professor of Dermatology and Allergy
Executive Director of the Institute of Allergology
Charité – Universitätsmedizin Berlin
Consulting Fee (e.g., Advisory Board): Amgen, ArgenX, AstraZeneca, Celldex, CSL Behring, Genentech, GIInnovation, Lilly, Moxie, Novartis, Pfizer, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB, Uriach
Contracted Research: Allakos, Amgen, ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech, GIInnovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Novartis, Pfizer, Roche, Sanofi/Regeneron, Third HarmonicBio, UCB, Uriach
Honoraria: Aralez, CSL Behring, Menarini, Novartis, Sanofi/Regeneron, Uriach
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Carole Drexel Nothing to disclose Colleen Heffner Nothing to disclose Stephanie Puccio Nothing to disclose Mary Coffee – Patient Participant Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Technical Support:For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.